The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
Meeting: how to define the organization of cancer screening using a set of distinct criteria?22/09/2021
We initiated a study aiming to achieve an international consensus on the essential and desirable criteria that a cancer screening program needs to fulfill to be considered as ‘organized’. This study is a blend of systematic review and a Delphi consensus process, seeking opinions of the global experts in cancer screening. After two rounds of online survey with 24 internaional experts ’input, we organized an expert meeting, during which we presented the outcomes and focussed on the discussion on selected criteria with the experts.
World Cancer Research Day 2021: Producing the evidence base for prevention20/09/2021
The IARC is marking World Cancer Research Day by publishing a collection of visuals to highlight some of the Agency’s recent achievements in cancer research, as well as the researchers behind these achievements. In this poster, Dr Partha Basu, Deputy Head, Early Detection, Prevention, and Infections Branch, highlighted IARC’s research related to HPV vaccines, including a trial in India to evaluate whether a single dose of the vaccine is as protective as two doses and a phase III trial for an HPV vaccine produced in India, could greatly reduce the cost and increase the supply of available vaccines, expanding protection against HPV-associated cancers to more of the most vulnerable groups. Visit the IARC World Cancer Research Day webpage and view the poster
CBIG-SCREEN: Kick-off meeting of WP617/09/2021
IARC scientists have held the virtual kick-off meeting of the Work package 6 of the H2020-GACD sponsored CBIG-SCREEN project. IARC is leading the WP6 that aims to pilot test the co-created tailored Cervical Cancer Screening Strategies in Estonia, Portugal and Romania. Discussions were held with collaborators around the preparatory work to do a capacity assessment of cervical cancer screening services in the three focus countries.
CBIG-Screen project website online15/09/2021
The International Agency for Research on Cancer (IARC) is participating in the CBIG-SCREEN project within the framework of the European Union Horizon2020 research and innovation programme. The CBIG-SCEEN project aims to reduce inequality by improving the offer of cervical cancer screening to vulnerable and underserved groups. Though Cervical Cancer Screening (CCS) programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and underused by subpopulations of vulnerable women, exacerbating inequality. Though Cervical Cancer Screening (CCS) programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and underused by subpopulations of vulnerable women, exacerbating inequality. Please visit http://cbig-screen.eu to find out more about cervical cancer screening and how to tackle inequalities
|Ringborg U., Berns A., Celis J.E., Heitor M., Tabernero J., Schuz J., Baumann M., Henrique R., Aapro M., Basu P., Beets-Tan R., Besse B., Cardoso F., Carneiro F., van den Eede G., Eggermont A., Frohling S., Galbraith S., Garralda E., Hanahan D., Hofmarcher T., Jonsson B., Kallioniemi O., Kasler M., Kondorosi E., Korbel J., Lacombe D., Carlos Machado J., Martin-Moreno J.M., Meunier F., Nagy P., Nuciforo P., Oberst S., Oliveiera J., Papatriantafyllou M., Ricciardi W., Roediger A., Ryll B., Schilsky R., Scocca G., Seruca R., Soares M., Steindorf K., Valentini V., Voest E., Weiderpass E., Wilking N., Wren A., Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Sep 13. doi: 10.1002/1878-0261.13078.|
|Mrabti H., Sauvaget C., Benider A., Bendahhou K., Selmouni F., Muwonge R., Alaoui L., Lucas E., Chami Y., Villain P., Abousselham L., Carvalho A.L., Bennani M., Errihani H., Sankaranarayanan R., Bekkali R., Basu P. Reply to: Chronic pain assessment and management during post-treatment follow up should be considered as a high value quality indicator for specialist breast cancer center. Breast. 2021 Sep 6:S0960-9776(21)00457-4. doi: 10.1016/j.breast.2021.09.003.|
|Gama R.R., Arantes L.M.R.B., Sorroche B.P., De Marchi P., Melendez M.E., Carvalho R.S., de Lima M.A., Vettore A.L., Carvalho A.L. Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. Sci Rep. 2021 Aug 12;11(1):16415.|